Genome-Wide Association Study Identifies Pharmacogenomic Variants Associated With Metformin Glycemic Response in African American Patients With Type 2 Diabetes
Authors' conclusion
We identified a novel and biologically plausible genetic variant associated with a change in HbA1c levels among African American patients on metformin monotherapy. These results highlight the importance of diversity in pharmacogenomic studies.
Study context
- Population
- Adult African American patients with T2D on metformin monotherapy, DIAMOND cohort (health system serving southeast Michigan), with genome-wide genotype data and longitudinal electronic records
- Participants
- 447 / 353 / 466
- Comparison
- DIAMOND African American vs Kaiser Permanente Northern California (KPNC) African American vs DIAMOND European American
- DIAMOND African Americann = 447
- KPNC African Americann = 353
- DIAMOND European Americann = 466
- Outcome
- Genomic variants correlated to changes in HbA1c on metformin monotherapy
Methodological detailsdiscovery and replication cohorts, meta-analysis
- Discovery and replication cohorts
- Meta-analysis
Pooled result
As reported in the abstract
Variant rs143276236 in ARFGEF3 associated with HbA1c change
- rs143276236 (ARFGEF3) met genome-wide significance, replicated in KPNC African Americans, significant in meta-analysis
- P = 1.17 × 10-9
Further pooled results
Replication in European Americans
- None of the significant discovery variants replicated in European American DIAMOND participants
Original publication
Genome-Wide Association Study Identifies Pharmacogenomic Variants Associated With Metformin Glycemic Response in African American Patients With Type 2 Diabetes. Diabetes Care. Published 28 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →